LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy^® (semaglutide), which includes both the medication and access to LifeMD’s virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy^® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare^® Pharmacy, with an additional $100 covering LifeMD’s clinical care, onboarding, and ongoing support.

Read more at globenewswire.com